Skin Cancer Treatment Market By Type, By Therapy, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
3.7. Patent Landscape

CHAPTER 4: SKIN CANCER TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Melanoma
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Non-Melanoma
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.3.4 Non-Melanoma Skin Cancer Treatment Market by Type
4.3.4.1 Basal Cell Carcinoma Market size and forecast, by region
4.3.4.2 Squamous Cell Carcinoma Market size and forecast, by region
4.3.4.3 Others Market size and forecast, by region

CHAPTER 5: SKIN CANCER TREATMENT MARKET, BY THERAPY
5.1 Overview
5.1.1 Market size and forecast
5.2 Immunotherapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Targeted Therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Chemotherapy
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country

CHAPTER 6: SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospitals Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 DrU.S.ores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: SKIN CANCER TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.2.1 North America Non-Melanoma Skin Cancer Treatment Market by Type
7.2.3 North America Market size and forecast, by Therapy
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Therapy
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Therapy
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Therapy
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.2.1 Europe Non-Melanoma Skin Cancer Treatment Market by Type
7.3.3 Europe Market size and forecast, by Therapy
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Therapy
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Therapy
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Therapy
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Therapy
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Therapy
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Therapy
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.2.1 Asia-Pacific Non-Melanoma Skin Cancer Treatment Market by Type
7.4.3 Asia-Pacific Market size and forecast, by Therapy
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Therapy
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Therapy
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Therapy
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Therapy
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Therapy
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Therapy
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.2.1 LAMEA Non-Melanoma Skin Cancer Treatment Market by Type
7.5.3 LAMEA Market size and forecast, by Therapy
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Therapy
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Therapy
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Therapy
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Therapy
7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 Amgen Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Bristol-Myers Squibb
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 F. Hoffmann-La Roche
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Glaxosmithkline plc
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 LEO Pharma
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck KGaA
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novartis AG
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Pfizer Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Regeneron Pharmaceuticals, Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Sun Pharmaceutical Industries Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

List of Tables
Table 1. Global Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 2. Skin Cancer Treatment Market, for Melanoma, by Region, 2021-2031 ($Million)
Table 3. Skin Cancer Treatment Market for Melanoma, by Country, 2021-2031 ($Million)
Table 4. Skin Cancer Treatment Market, for Non-Melanoma, by Region, 2021-2031 ($Million)
Table 5. Skin Cancer Treatment Market for Non-Melanoma, by Country, 2021-2031 ($Million)
Table 6. Global Non-Melanoma Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 7. Skin Cancer Treatment Market, for Basal Cell Carcinoma, by Region, 2021-2031 ($Million)
Table 8. Skin Cancer Treatment Market, for Squamous Cell Carcinoma, by Region, 2021-2031 ($Million)
Table 9. Skin Cancer Treatment Market, for Others, by Region, 2021-2031 ($Million)
Table 10. Global Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 11. Skin Cancer Treatment Market, for Immunotherapy, by Region, 2021-2031 ($Million)
Table 12. Skin Cancer Treatment Market for Immunotherapy, by Country, 2021-2031 ($Million)
Table 13. Skin Cancer Treatment Market, for Targeted Therapy, by Region, 2021-2031 ($Million)
Table 14. Skin Cancer Treatment Market for Targeted Therapy, by Country, 2021-2031 ($Million)
Table 15. Skin Cancer Treatment Market, for Chemotherapy, by Region, 2021-2031 ($Million)
Table 16. Skin Cancer Treatment Market for Chemotherapy, by Country, 2021-2031 ($Million)
Table 17. Global Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 18. Skin Cancer Treatment Market, for Hospitals Pharmacies, by Region, 2021-2031 ($Million)
Table 19. Skin Cancer Treatment Market for Hospitals Pharmacies, by Country, 2021-2031 ($Million)
Table 20. Skin Cancer Treatment Market, for DrU.S.ores and Retail Pharmacies, by Region, 2021-2031 ($Million)
Table 21. Skin Cancer Treatment Market for DrU.S.ores and Retail Pharmacies, by Country, 2021-2031 ($Million)
Table 22. Skin Cancer Treatment Market, for Online Providers, by Region, 2021-2031 ($Million)
Table 23. Skin Cancer Treatment Market for Online Providers, by Country, 2021-2031 ($Million)
Table 24. Skin Cancer Treatment Market, by Region, 2021-2031 ($Million)
Table 25. North America Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 26. North America Non-Melanoma Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 27. North America Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 28. North America Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 29. North America Skin Cancer Treatment Market, by Country, 2021-2031 ($Million)
Table 30. U.S. Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 31. U.S. Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 32. U.S. Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 33. Canada Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 34. Canada Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 35. Canada Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 36. Mexico Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 37. Mexico Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 38. Mexico Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 39. Europe Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 40. Europe Non-Melanoma Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 41. Europe Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 42. Europe Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 43. Europe Skin Cancer Treatment Market, by Country, 2021-2031 ($Million)
Table 44. Germany Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 45. Germany Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 46. Germany Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 47. France Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 48. France Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 49. France Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 50. U.S.in Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 51. U.S.in Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 52. U.S.in Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 53. Italy Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 54. Italy Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 55. Italy Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 56. Spain Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 57. Spain Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 58. Spain Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 59. Rest of Europe Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 60. Rest of Europe Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 61. Rest of Europe Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 62. Asia-Pacific Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 63. Asia-Pacific Non-Melanoma Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 64. Asia-Pacific Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 65. Asia-Pacific Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 66. Asia-Pacific Skin Cancer Treatment Market, by Country, 2021-2031 ($Million)
Table 67. Japan Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 68. Japan Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 69. Japan Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 70. China Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 71. China Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 72. China Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 73. India Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 74. India Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 75. India Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 76. Australia Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 77. Australia Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 78. Australia Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 79. South Korea Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 80. South Korea Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 81. South Korea Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 82. Rest of Asia-Pacific Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 83. Rest of Asia-Pacific Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 84. Rest of Asia-Pacific Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 85. LAMEA Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 86. LAMEA Non-Melanoma Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 87. LAMEA Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 88. LAMEA Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 89. LAMEA Skin Cancer Treatment Market, by Country, 2021-2031 ($Million)
Table 90. Brazil Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 91. Brazil Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 92. Brazil Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 93. Saudi Arabia Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 94. Saudi Arabia Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 95. Saudi Arabia Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 96. South Africa Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 97. South Africa Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 98. South Africa Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 99. Rest of LAMEA Skin Cancer Treatment Market, by Type, 2021-2031 ($Million)
Table 100. Rest of LAMEA Skin Cancer Treatment Market, by Therapy, 2021-2031 ($Million)
Table 101. Rest of LAMEA Skin Cancer Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 102. Amgen Inc.: Company Snapshot
Table 103. Amgen Inc.: Operating Segments
Table 104. Amgen Inc.: Product Portfolio
Table 105. Amgen Inc.: Net Sales
Table 106. Amgen Inc.: Key Strategies
Table 107. Bristol-Myers Squibb: Company Snapshot
Table 108. Bristol-Myers Squibb: Operating Segments
Table 109. Bristol-Myers Squibb: Product Portfolio
Table 110. Bristol-Myers Squibb: Net Sales
Table 111. Bristol-Myers Squibb: Key Strategies
Table 112. F. Hoffmann-La Roche: Company Snapshot
Table 113. F. Hoffmann-La Roche: Operating Segments
Table 114. F. Hoffmann-La Roche: Product Portfolio
Table 115. F. Hoffmann-La Roche: Net Sales
Table 116. F. Hoffmann-La Roche: Key Strategies
Table 117. GlaxoSmithKline PLC: Company Snapshot
Table 118. GlaxoSmithKline PLC: Operating Segments
Table 119. GlaxoSmithKline PLC: Product Portfolio
Table 120. GlaxoSmithKline PLC: Net Sales
Table 121. GlaxoSmithKline PLC: Key Strategies
Table 122. Leo Pharma: Company Snapshot
Table 123. Leo Pharma: Operating Segments
Table 124. Leo Pharma: Product Portfolio
Table 125. Leo Pharma: Net Sales
Table 126. Leo Pharma: Key Strategies
Table 127. Merck KGaA: Company Snapshot
Table 128. Merck KGaA: Operating Segments
Table 129. Merck KGaA: Product Portfolio
Table 130. Merck KGaA: Net Sales
Table 131. Merck KGaA: Key Strategies
Table 132. Novartis AG: Company Snapshot
Table 133. Novartis AG: Operating Segments
Table 134. Novartis AG: Product Portfolio
Table 135. Novartis AG: Net Sales
Table 136. Novartis AG: Key Strategies
Table 137. Pfizer Inc.: Company Snapshot
Table 138. Pfizer Inc.: Operating Segments
Table 139. Pfizer Inc.: Product Portfolio
Table 140. Pfizer Inc.: Net Sales
Table 141. Pfizer Inc.: Key Strategies
Table 142. Regeneron Pharmaceuticals, Inc.: Company Snapshot
Table 143. Regeneron Pharmaceuticals, Inc.: Operating Segments
Table 144. Regeneron Pharmaceuticals, Inc.: Product Portfolio
Table 145. Regeneron Pharmaceuticals, Inc.: Net Sales
Table 146. Regeneron Pharmaceuticals, Inc.: Key Strategies
Table 147. Sun Pharmaceutical Industries Ltd.: Company Snapshot
Table 148. Sun Pharmaceutical Industries Ltd.: Operating Segments
Table 149. Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 150. Sun Pharmaceutical Industries Ltd.: Net Sales
Table 151. Sun Pharmaceutical Industries Ltd.: Key Strategies

List of Figures
Figure 1. Skin Cancer Treatment Market Segmentation
Figure 2. Skin Cancer Treatment Market, 2021-2031
Figure 3. Skin Cancer Treatment Market, 2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Skin Cancer Treatment Mark.:Drivers, Restraints and Opportunities
Figure 12. Patent Analysis by Company
Figure 13. Patent Analysis by Country
Figure 14. Skin Cancer Treatment Market, By Type, 2021(%)
Figure 15. Comparative Share Analysis of Melanoma Skin Cancer Treatment Market, 2021-2031(%)
Figure 16. Comparative Share Analysis of Non-Melanoma Skin Cancer Treatment Market, 2021-2031(%)
Figure 17. Skin Cancer Treatment Market, By Therapy, 2021(%)
Figure 18. Comparative Share Analysis of Immunotherapy Skin Cancer Treatment Market, 2021-2031(%)
Figure 19. Comparative Share Analysis of Targeted Therapy Skin Cancer Treatment Market, 2021-2031(%)
Figure 20. Comparative Share Analysis of Chemotherapy Skin Cancer Treatment Market, 2021-2031(%)
Figure 21. Skin Cancer Treatment Market, By Distribution Channel, 2021(%)
Figure 22. Comparative Share Analysis of Hospitals Pharmacies Skin Cancer Treatment Market, 2021-2031(%)
Figure 23. Comparative Share Analysis of Drug Stores and Retail Pharmacies Skin Cancer Treatment Market, 2021-2031(%)
Figure 24. Comparative Share Analysis of Online Providers Skin Cancer Treatment Market, 2021-2031(%)
Figure 25. Skin Cancer Treatment Market by Region, 2021
Figure 26. U.S. Skin Cancer Treatment Market, 2021-2031($Million)
Figure 27. Canada Skin Cancer Treatment Market, 2021-2031($Million)
Figure 28. Mexico Skin Cancer Treatment Market, 2021-2031($Million)
Figure 29. Germany Skin Cancer Treatment Market, 2021-2031($Million)
Figure 30. France Skin Cancer Treatment Market, 2021-2031($Million)
Figure 31. Uk Skin Cancer Treatment Market, 2021-2031($Million)
Figure 32. Italy Skin Cancer Treatment Market, 2021-2031($Million)
Figure 33. Spain Skin Cancer Treatment Market, 2021-2031($Million)
Figure 34. Rest of Europe Skin Cancer Treatment Market, 2021-2031($Million)
Figure 35. Japan Skin Cancer Treatment Market, 2021-2031($Million)
Figure 36. China Skin Cancer Treatment Market, 2021-2031($Million)
Figure 37. India Skin Cancer Treatment Market, 2021-2031($Million)
Figure 38. Australia Skin Cancer Treatment Market, 2021-2031($Million)
Figure 39. South Korea Skin Cancer Treatment Market, 2021-2031($Million)
Figure 40. Rest of Asia-Pacific Skin Cancer Treatment Market, 2021-2031($Million)
Figure 41. Brazil Skin Cancer Treatment Market, 2021-2031($Million)
Figure 42. Saudi Arabia Skin Cancer Treatment Market, 2021-2031($Million)
Figure 43. South Africa Skin Cancer Treatment Market, 2021-2031($Million)
Figure 44. Rest of LAMEA Skin Cancer Treatment Market, 2021-2031($Million)
Figure 45. Top Winning Strategies, by Year
Figure 46. Top Winning Strategies, by Development
Figure 47. Top Winning Strategies, by Company
Figure 48. Product Mapping of Top 10 Players
Figure 49. Competitive Dashboard
Figure 50. Competitive Heatmap of Top 10 Key Players
Figure 51. Amgen Inc.: Net Sales, ($Million)
Figure 52. Bristol-Myers Squib.: Net Sales, ($Million)
Figure 53. F. Hoffmann-La Roch.: Net Sales, ($Million)
Figure 54. GlaxoSmithKline pl.: Net Sales, ($Million)
Figure 55. Leo Pharm.: Net Sales, ($Million)
Figure 56. Merck Kga.: Net Sales, ($Million)
Figure 57. Novartis A.: Net Sales, ($Million)
Figure 58. Pfizer Inc.: Net Sales, ($Million)
Figure 59. Regeneron Pharmaceuticals, Inc.: Net Sales, ($Million)
Figure 60. Sun Pharmaceutical Industries Ltd.: Net Sales, ($Million)

Executive Summary

According to the report, “Skin Cancer Treatment Market," the skin cancer treatment market size was valued at $7.2 billion in 2021, and is estimated to reach $14.5 billion by 2031, growing at a CAGR of 7.3% from 2022 to 2031.

Skin cancer is the most prevalent type of cancer across the globe. Melanoma or non-melanoma skin cancer (NMSC) are the two main categories of skin cancer. Due to inadequate diagnostic standards and underreporting, it is challenging to pinpoint the exact incidences of skin cancer. Head and neck are common areas where skin malignancies are found, which can cause serious morbidity during diagnosis and treatment. Medicated treatment options include chemotherapy, immunotherapy, and targeted therapy. Sunscreen use is essential for proper sun safety. The primary etiological component in the emergence of cutaneous cancers is ultraviolet (UV) sun radiation. Majority of NMSC and melanoma cases can be attributed to UV exposure.

Increase in prevalence of skin cancer cases including melanoma and non-melanoma are the major factors contributes, to drive the growth of skin cancer treatment market size. For instance, according to the Skin Cancer Foundation, U.S. has reported about 3.6 million populations with basal cell carcinoma and 1.8 million people with squamous cell carcinoma in 2022. From the same report it was estimated that, skin cancer is most common type of cancer in the U.S. 1 in 5 Americans will develop skin cancer and more than 2 people die with skin cancer.

In addition, increase in initiative taken by government and key players involved in manufacturing and development of innovative therapeutics in the healthcare sector for effective treatment of skin cancer are some skin cancer treatment market trends leads to the market growth. For instance, in 2020, Genentech, a member of leading pharmaceutical company Roche announced the product approval from Food and Drug Administration (FDA) for products Tecentriq (atezolizumab) and Cotellic (cobimetinib) collectively to treat patients with BRAF V600 mutation effectively.

Furthermore, rise in product approvals for effective management of skin cancer by regulatory authorities also boost the market growth. For instance, in 2021, the FDA announced approval of the first immunotherapy product, PD-1 inhibitor Libtayo to treat basal cell carcinoma, which has a higher chance of success than the previously used hedgehog pathway inhibitor (HHI). Increased demand for immunotherapy and targeted based therapy treatments and increased awareness about skin cancer treatments are the opportunities for market growth in forecast period. However, side effects associated with use of chemotherapy for skin cancer treatment hampers the market growth.

COVID-19 is a large family of viruses that causes illness ranging from common cold to more severe respiratory diseases. The global skin cancer treatment industry also declined in 2020 due to global economic recession led by COVID-19. The main factor is the delays in care, that patients with skin cancer experience in hospitals because of the possibility of contracting COVID-19 infection. The COVID-19 global public health crisis has had an effect on almost every industry.

The global skin cancer treatment market is segmented by type, therapy, distribution channel and region. By type, the market is classified into melanoma and non-melanoma. By therapy, the market is classified into immunotherapy, targeted therapy, and chemotherapy. By distribution channel, the market is classified into hospitals pharmacies, drug stores & retail pharmacies and online providers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Depending on type, the market is divided into melanoma and non- melanoma. The melanoma segment dominated the market in 2021, and is also expected to witness highest CAGR during skin cancer treatment market forecast, owing to increase in number of populations affected with melanoma. The non-melanoma type segment is expected to grow during the forecast period, owing to increase in number of populations with non-melanoma and product launches for non-melanoma type of skin cancer treatment.

Depending on therapy, the market is divided into immunotherapy, targeted therapy, and chemotherapy. The immunotherapy segment dominated the market in 2021, and is also expected to witness highest CAGR during the forecast period, owing to increase in demand for immunotherapy-based skin cancer treatments and minimum side effects associated with use of immunotherapy drugs. The targeted therapy segment is estimated to grow during the forecast period, owing to increase in product launches, less side effects associated with targeted based therapies, higher efficacy, and accuracy.

Depending on distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies and online providers. The drug stores & retail pharmacies segment dominated the market in 2021, owing to its presence in commercial areas of the community. The online provider segment is expected to witness highest CAGR of during the forecast period, owing to popular medium for purchase of medicines.

By region, North America accounted for majority of the global skin cancer treatment market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in skin cancer treatment techniques, R & D of advanced drugs for allergic conjunctivitis and presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in patient population, development of healthcare infrastructure, and increase in investment projects in the region.

Key Findings of the Study

• By type, the melanoma segment was the highest contributor to the skin cancer treatment industry in 2021.
• By therapy, the immunotherapy segment was the highest contributor to the market in 2021.
• Depending on distribution channel, the drug stores & retail pharmacies segment was the highest contributor in 2021, and is expected to continue this trend during the forecast period.
• Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the skin cancer treatment market analysis.

Companies Mentioned

• Amgen Inc.
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Glaxosmithkline plc
• LEO Pharma
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries Ltd.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.